Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q3 2020 · 10-Q
Revenue$148.00K$148.00K−19.6% vs Q3 2019 Net Income-$6.60M-$6.60MN/M vs Q3 2019 EPS Diluted-$0.68-$0.68N/M vs Q3 2019 Operating Income-$6,512,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,567,000N/M Margins · derivedOperating margin-4400.0%−1412.0 pt vs Q3 2019
Net margin-4458.8%−1390.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 13, 2020 · 44 d after period end